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Natural killer (NK) cells are a population of innate immune cells known to play a piv-
otal role against tumor spread. In multiple murine models, it was shown that physical 
exercise had the potential to increase NK cell antitumor activity through their mobi-
lization and tissue redistribution in an interleukin (IL)- 6 and epinephrine- dependent 
manner. The translation of this finding to patients is unclear. In this randomized pilot 
trial, we analyzed blood samples of patients with resectable breast or colon cancer 
who were randomized into an evidence- based moderate- high intensity resistance 
and aerobic exercise intervention (n = 8) or a control group (n = 6) during the first 
9– 12 weeks of (neo)adjuvant chemotherapy. In this pilot, we did not solely focus on 
statistical significance, but also explored whether average between- group differences 
reached 10%. NK cell degranulation was preserved in the exercise group whereas 
it decreased in the control group resulting in a between- group difference of 11.4% 
CD107a+ degranulated NK cells (95%CI = 0.57;22.3, p = 0.04) in the presence and 
13.8% (95%CI = −2.5;30.0, p = 0.09) in the absence of an anti- epidermal growth 
factor receptor monoclonal antibody (EGFR- mAb). In line, the between- group dif-
ference of tumor cell lysis was 7.4% (95%CI  =  −9.1;23.9, p  =  0.34), and 13.7% 
(95%CI = −10.1;37.5, p = 0.23) in favor of the exercise group in the presence or ab-
sence of EGFR mAb, respectively. Current explorative analyses showed that exercise 
during (neo)adjuvant chemotherapy may benefit NK cell activity. Future studies with 
a larger sample size are needed to confirm this finding and to establish its clinical 
potential.
Trial registration: Dutch trial register number NTR4105.
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1 |  INTRODUCTION
Natural killer (NK) cells are innate immune cells that play a 
key role in the defense against tumor or virus- infected cells. 
Their activity is regulated by a balance of activating and inhib-
itory receptors. The former comprises the natural killer group 
2 member (NKG2)D/C/E, the natural cytotoxicity receptors 
(NCRs), such as NKp30/44/46, and the DNAX Accessory 
Molecule- 1 (DNAM1) while the latter includes the killer cell 
immunoglobulin- like receptors (KIR)2D and NKG2A (Vivier 
et al., 2008). Human NK cells can be divided into two main 
subsets with distinct immune functions: the CD56dimCD16+ 
NK cells traditionally described as more cytotoxic and the 
CD56brigthCD16low/neg characterized by the ability to produce 
high levels of cytokines (Cooper et al., 2001; Vivier et al., 
2008). NK cell activity can be compromised by cancer and 
previous studies demonstrated that patients with cancer who 
have activated NK cells have a better prognosis (Takeuchi 
et al., 2001; Tartter et al., 1987). Activated NK cells can also 
improve the response to antibody- based therapies (Beano 
et al., 2008; Liljefors et al., 2003). However, chemotherapy 
among other anti- tumor therapies, can lead to reduced NK 
cell activity (Beitsch et al., 1994; Brenner & Margolese, 
1991; Sewell et al., 1993) increasing the need for strategies to 
maintain it. Physical exercise plays a role in the regulation of 
the immune system and, potentially, in cancer control (Idorn 
& Hojman, 2016). In different mouse models, a direct inhib-
itory effect of exercise on tumor growth was found (Pedersen 
et al., 2016), where the exercise- induced release of epineph-
rine and interleukin (IL)- 6 into the bloodstream resulted in 
mobilization, redistribution, and activation of NK cells, with 
increased infiltration of activated NK cells (Pedersen et al., 
2016). It is unclear whether these findings can be translated 
to patients. Studies examining NK cell activation after ex-
ercise interventions in patients with cancer are scarce, and 
none were conducted during chemotherapy (Zimmer et al., 
2017). With this pilot trial, we aimed to explore the effects of 
exercise on NK cell phenotype and function, and plasma IL- 6 
levels during chemotherapy treatment.
2 |  METHODS
2.1 | Design and participants
This study was part of the Mechanisms of Training In pa-
tients with Cancer (METRIC) a randomized multicenter pilot 
trial conducted in three enrolling sites in the Netherlands: 
Amsterdam UMC (location VU University Medical Center), 
Amstelland Hospital, and the Netherlands Cancer Institute/
Antoni van Leeuwenhoek Hospital. Patients diagnosed 
with resectable colon (stage II/III) or breast cancer stage 
(I/II/III) scheduled to receive (neo)adjuvant chemotherapy 
were randomized into an evidence- based moderate- high in-
tensity resistance and aerobic exercise intervention (Waart 
et al., 2015) during the first 9– 12  weeks of chemotherapy 
or to a control group. Blood samples were obtained before 
the start of chemotherapy and randomization (T0), and after 
9– 12 weeks of chemotherapy (T1).
Patient exclusion criteria included (1) the inability to 
perform basic activities of daily living such as walking or 
cycling, (2) the presence of cognitive disorders or severe 
emotional instability, (3) the existence of other disabling co- 
morbidities that hampered physical activity, (4) the inability 
to read Dutch, (5) concurrent or prior anticancer therapies, (6) 
prednisone therapy concurrent or up to 6 months before diag-
nosis, and (7) insulin dependency. This study was conducted 
according to the declaration of Helsinki and it was approved 
by the medical ethics committee (VUmc: 109 2012/430) and 
registered in the Dutch Trial Registry in 2013 (NL3944). All 
patients signed an informed consent form prior to participa-
tion in the study.
2.2 | Exercise intervention and control group
The exercise intervention consisted of two weekly 60- min 
exercise sessions that were supervised by a physiotherapist 
specifically educated to train patients with cancer. Each ex-
ercise session started with warming- up exercises, followed 
by 20 min resistance exercise training and 30 min aerobic 
exercise training at moderate- high intensity, and ended with 
a cooling down (Buffart et al., 2020). During the first ap-
pointment, maximal short exercise capacity and muscle 
strength were determined through a steep ramp test and in-
direct 1- repetition maximum test, respectively. Afterward, 
these tests were repeated every three weeks to ensure ad-
equate training intensity. Further details about the study pro-
cedures and exercise intervention are presented elsewhere 
(Buffart et al., 2020). Patients in the control group were of-
fered the evidence- based exercise intervention during the 
second half of the chemotherapy (after the T1 assessments) 
to decrease the number of drop- outs due to disliking of the 
randomization and reduce non- compliance (Steins Bisschop 
et al., 2015).
2.3 | NK cell degranulation and cytotoxicity
NK cell degranulation and cytotoxicity were analyzed in all 
blood samples. The assays were performed in the presence 
and absence of the anti- epidermal growth factor receptor 
monoclonal antibody cetuximab (Merck) (EGFR- mAb) to 
evaluate variations in NK cell- mediated antibody- dependent 
cell cytotoxicity (ADCC). Peripheral blood mononuclear 
cells (PBMCs) were isolated from peripheral blood using 
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CPT tubes (BD biosciences) on a density gradient centrifu-
gation. Afterward, isolated PBMC were suspended in Fetal 
Calf Serum (FCS, Integro), and freezing medium, contain-
ing 25% Dimethyl Sulfoxide (DMSO, Sigma Aldrich) and 
FCS, was added to the cells to reach a final DMSO concen-
tration of 12.5%. Thereafter, the cells were frozen using a 
controlled rate freezing system and stored in liquid nitrogen. 
At the time of use, the cells were rapidly thawed and diluted 
in RPMI (Gibco, Thermo Fischer Scientific) containing 10% 
FCS, 100  U/ml penicillin, 100  μ/ml streptomycin, 0,3  mg/
ml Glutamine (PSG, Gibco, Thermo Fischer Scientific), and 
2- mercaptoethanol (2- ME, Merck) (details on PBMC viabil-
ity after thawing are shown in the Supplementary Material). 
Subsequently, thawed PBMCs underwent a monocyte deple-
tion adherence step (to eliminate the possibility of ADCC 
by [non- classical] monocytes) before being activated over-
night with 1000 U/ml IL- 2 (Novartis) and 10  ng/ml IL- 15 
(ThermoFisher). Next, the monocyte- depleted PBMC were 
co- cultured at an effector to target ratio of 4:1 with the 
EGFR+ A431 (epidermoid carcinoma) cell line that was pre- 
incubated for 1 h in the presence or absence of EGFR- mAb 
and subsequently washed. The cells were plated in a 96 wells 
plate in a total volume of 200 μl RPMI for 4 h at 37◦C. NK 
cell degranulation was based on the percentage of CD107a+ 
(PE, ThermoFisher) NK cells, defined as CD45+ (AF700, 
Biolegend), CD56+ (APC- Vio770, Miltenyi), and CD3− 
(BV711, BD Horizon). Tumor cell lysis was based on the rel-
ative percentage of cytotoxicity [100 - relative percentage of 
living tumor cells, defined as Epcam+ (FITC, Biolegend) and 
7AAD− (Sigma Aldrich), quantified with QUANTI BEADS 
F I G U R E  1  Gating strategy for the degranulation (a) and cytotoxicity (b) assays. Control plot are shown: culture of solely PBMC for the 
degranulation assay and culture of solely A431 for the cytotoxicity assay
(a)
(b)
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(Invitrogen, Thermo Fisher Scientific)]. Examples of the gat-
ing strategy can be found in Figure 1.
2.4 | NK cell receptor analysis
From a subgroup of patients (4 control and 4 intervention) pe-
ripheral blood NK cells were tested for the expression of mul-
tiple NK cell receptors using flow cytometry (LSRFortessa™, 
BD). The following mAbs conjugated with the listed fluo-
rochromes were used for cell staining: PanKIR2D FITC, 
NKG2C PE, NKG2A PE- vio770, NKp46 APC, NKp44 PE- 
Vio770, CD56 APC- Vio770 (all from Miltenyi), NKG2D 
APC (BD Pharmingen), DNAM1 AF700 (RnD systems), 
NKp30 PE (Biolegend), CD25 FITC, CD3 BV711 (both from 
BD biosciences) and CD16 BV786 (from BD Horizon). The 
analyses were performed on both the CD56dimCD16+ and the 
CD56brightCD16low/neg NK cell subsets. All flow cytometry 
data were analyzed with the software Kaluza 1.3 (Beckman 
Coulter). Examples of the gating strategy are shown in Figure 2. 
Details on the catalog and clone numbers of all antibodies 
used can be found in Table S1.
F I G U R E  2  Example of gating strategy for the NK cell receptor analysis. (a) Backbone analysis common to the phenotypical and the functional 
panel. (b) FMO tube stained with solely the backbone panel used as guidance for the gating of the phenotypical and functional panels. (c) 
Phenotypical panel which includes PanKIR2D (FITC), NKG2C (PE), NKG2A (PE- Cy7), NKG2D (APC), and DNAM 1 (AF700). (d) Functional 
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2.5 | IL- 6 analysis
At T0 and T1, plasma IL- 6 levels were assessed via an 
enzyme- linked immunosorbent  assay (ELISA, R&D 
systems).
2.6 | Statistical analysis
Within- group and between- group differences in NK cell ac-
tivity and IL- 6 levels were examined with linear regression 
analyses. In the models, the posttest value was the dependent 
variable. When examining within- group changes, we included 
the baseline as independent variable in the model for the study 
arms separately. To examine between- group differences, the 
intervention was included as independent variable and the 
models were adjusted for the baseline value of the study arm. 
Unstandardized regression coefficients, representing the aver-
age change in the dependent variable over time within each 
group or the difference between exercise and control group, 
and corresponding 95% confidence intervals (CI) were pre-
sented. Due to the small sample size and not normal distribu-
tion of the NK receptor results, a Mann- Whitney U test was 
used to examine the difference between groups in the changes 
from baseline to posttest. Median and interquartile range 
(IQR) were shown. Additionally, due to the small sample size, 
the interpretation of the results was based on potentially rel-
evant differences (≥10% group differences), instead of solely 
the p- value (Panagiotakos, 2008; Prel et al., 2009). All analy-
ses were conducted using SPSS (IBM SPSS Statistics 22).
3 |  RESULTS
Of the 30 patients enrolled, 22 completed the follow- up as-
sessments. We were able to analyze blood samples of 14 of 
these patients (8 exercise; 6 control). Patient characteristics 
are shown in Table 1.
NK cell degranulation after (neo)adjuvant chemotherapy 
was preserved in the exercise group whereas it decreased in 
the control group, resulting in a between- group difference of 
13.8% (95%CI = −2.5;30.0, p = 0.09), in favor of the exer-
cise group (Table 2; Figure 3a). A similar result was found 
when PBMCs were co- cultured with EGFR- mAb coated 
A431 cells (β = 11.4%, 95%CI = 0.57;22.3, p = 0.04).
The relative percentages of cytotoxicity showed an aver-
age increase in the exercise group and decrease in the control 
group (Table 2; Figure 3b), resulting in a (non- significant) 
between- group difference of 7.4%, (95%CI  =  −9.1; 23.9, 
p = 0.34) in the presence and 13.7%, (95%CI = −10.1;37.5, 
p = 0.23) in the absence of EGFR- mAb.
A significantly higher expression of the activating recep-
tor NKp46 was found on CD56dimCD16+ NK cells in the 
exercise group compared to the control group with a median 
change of respectively 3.6 (IQR:3.4;7.5) and −0.7 (IQR:- 
3.0;2.0) in median fluorescence intensity (Table 2; Figure 
3c). No additional relevant differences in expression were 
found for the other NK cell receptors on the CD56dimCD16+ 
NK cells (Table 2) as well as on the CD56brightCD16low/neg 
NK cells (Table S2).
Finally, though not statistically significant, plasma 
IL- 6 levels were slightly increased in the exercise group com-
pared to the control group (β = 0.2 pg/ml, 95%CI = −0.1;0.5; 
p = 0.10) (Table 2).
4 |  DISCUSSION
In this randomized controlled pilot trial, we evaluated the 
effect of a combined resistance and aerobic exercise inter-
vention on NK cell phenotype and function in patients with 
breast or colon cancer undergoing (neo)adjuvant chemother-
apy. Due to the small sample size and the explorative na-
ture of this pilot study, the results should be viewed more 
as hypothesis- generating than hypothesis- testing. The results 
suggest that exercise may preserve NK cell activity indicated 
by preserved degranulation levels upon exposure to tumor 
cells and increased expression of the activating receptor 
NKp46 on effector NK cells (Cooper et al., 2001). Moreover, 
an average between- group difference of 13.7% in PBMC me-
diated cytotoxicity in favor of the exercise group was found 
T A B L E  1  Demographic and clinical characteristics of patients 






Age, mean (SD) years 55.1 (14.8) 60.7 (7.6)
Gender, n (%) female 6 (75) 6 (100)
BMI, mean (SD) kg/m2 25.8 (6.9) 28.7 (4.5)
Marital status. n (%) married 5 (62.5) 4 (66.7)
Education level, n (%) high 3 (37.5) 2 (33.3)
Employment status, n (%) working 5 (62.5) 3 (50.0)
Smoking, n (%) yes 0 (0) 0 (0)
Exercise history, n (%) yes 6 (75.0) 5 (83.3)
Co- morbidities, *n (%) yes 3 (37.5) 4 (66.7)
Cancer type and treatment, n (%)
Breast cancer, Adjuvant 2 (25) 3 (50)
Breast cancer, Neoadjuvant 2 (25) 1 (17)
Colon cancer, Adjuvant 4 (50) 2 (33)
Abbreviations: BMI, body mass index; SD, standard deviation.
*Any of the following comorbidities: cardiovascular disease, high blood 
pressure, osteoporosis, asthma, neurological disease, gastrointestinal disease, 
psychiatric problems, degenerative disease, and migraine.
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T A B L E  2  NK cell degranulation, CD56dimCD16pos NK cells phenotype, lysis of A431 tumor cells and IL- 6 plasma levels at baseline and at 
9– 12 weeks and changes within and between the exercise intervention and control group
Variable N Baseline 9– 12 weeks Within- Group change Between- Group change
Mean (SD) Mean (SD) β (95% CI) β (95% CI) p value
%CD107apos NK cells
A431 vs PBMC
Exercise 8 34.7 (19.6) 36.1 (20.4) 1.4 (−5.3; 8.2) 13.8 (−2.5; 30.0) 0.09
Control 6 42.7 (22.2) 26.6 (10.1) −16.1 (−40.2; 8.0)
+ EGFR- mAb
Exercise 8 65.4 (17.6) 67.5 (14.4) 2.2 (−8.3; 12.7) 11.4 (0.6; 22.3) 0.04
Control 6 63.8 (14.3) 55.2 (9.8) −8.6 (−18.1; 0.9)
Relative Percentage of Cytotoxicity
A431 vs PBMC
Exercise 8 41.5 (28.1) 49.1 (21.1) 7.6 (−10.8; 26.0) 13.7 (10.1; 37.5) 0.23
Control 6 40.8 (28.7) 35.0 (31.5) −5.8 (−28.9; 17.3)
+ EGFR- mAb
Exercise 8 62.1 (29.6) 62.6 (24.2) 0.5 (−12.1; 13.1) 7.4 (9.1; 23.9) 0.34
Control 6 60.4 (18.1) 53.9 (22.9) −6.5 (−21.0; 8.0)
IL−6 (pg/ml)
Exercise 8 0.2 (0.1) 0.5 (0.2) 0.3 (0.1; 0.5) 0.2 (−0.1; 0.5) 0.10
Control 6 0.3 (0.1) 0.4 (0.2) 0.1 (−0.2; 0.3)
CD56dimCD16pos NK cells – Median Fluorescence Intensity
Variable N Baseline 9– 12 weeks Within- group change Between- group change
Median (IQR) Median (IQR) Median (IQR) p- value
KIR2D
Exercise 4 4.9 (1.8;5.7) 3.0 (0.7;6.6) −0.4 (−3.2;1.4) 0.686
Control 4 3.2 (0.9;4.1) 2.6 (0.3;4.5) 0.1 (−1.8;1.0)
NKG2A
Exercise 4 3.4 (2.4;16.2) 8.9 (4.2;22.9) 4.7 (1.5;7.6) 0.486
Control 4 3.0 (2.1;4.6) 3.6 (2.3;25.6) 0.6 (−0.2;21.3)
DNAM1
Exercise 4 2.1 (2.0;3.0) 2.0 (2.0;2.1) −0.1 (−1.0;0.02) 0.886
Control 4 1.9 (1.8;2.7) 1.9 (1.8;2.4) −0.03 (−0.3;0.1)
NKG2C
Exercise 4 0.6 (0.4;4.9) 0.8 (0.7;1.3) 0.2 (−3.6;0.3) 0.686
Control 4 0.4 (0.3;0.5) 0.6 (0.4;0.9) 0.2 (0.1;0.4)
NKG2D
Exercise 4 1.3 (1.15;1.6) 2.8 (2.7;3.0) 1.4 (1.1;1.8) 0.343
Control 4 1.5 (1.3;1.8) 2.3 (1.9;3.5) 0.6 (0.4;2.1)
NKp30
Exercise 4 2.1 (1.3;3.2) 3.5 (2.5;5.2) 1.1 (0.1;3.4) 0.686
Control 4 3.0 (1.5;4.2) 3.8 (1.6;5.2) 0.3 (−0.1;1.7)
NKp44
Exercise 4 0.5 (0.4;0.6) 0.2 (−0.13;0.3) −0.2 (−0.7;−0.1) 0.114
Control 4 0.3 (0.2;0.6) 0.6 (0.5;0.7) 0.3 (0.0;0.4)
(continues)
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suggesting that it is worth conducting a future trial investi-
gating the effect of exercise during chemotherapy on PBMC 
mediated cytotoxicity. The results of this study could be used 
to inform sample size calculations of such a trial. In line, an 
average between- group difference of 7.4% was observed 
when tumor cells were exposed to an EGFR- mAb. Finally, 
the IL- 6 levels were found slightly increased during exercise, 
which aligns with published data from mouse models, and 
may be related to NK cell re- distribution to the tumor mi-
croenvironment (Pedersen et al., 2016). Nevertheless, larger 
differences would likely be found when analyzing the acute 
exercise- dependent IL- 6 release. It is currently unclear how 
the approximate 10% difference in NK cell activity trans-
lates to clinical outcomes. However, higher NK cell activ-
ity has been associated with better response to neoadjuvant 
chemotherapy (Kim et al., 2019) and antibody- based thera-
pies (Beano et al., 2008; Liljefors et al., 2003) suggesting that 
combining cancer therapies with exercise might be benefi-
cial. Moreover, previous studies showed that the expression 
of NKp46 was positively associated with overall survival in 
F I G U R E  3  (a) Changes from baseline 
of pbNK cell degranulation after 4h co- 
culture with A431 in presence and absence 
of EGFR- mAb. E:T ratio 4:1. N = 8 
exercise cohort (green) and N = 6 control 
cohort (red). The bars represent the mean 
±SD. (b) Changes from baseline of the 
relative percentage of cytotoxicity after 4h 
A431 and PBMC co- culture in presence 
and absence of EGFR- mAB. E:T ratio 4:1. 
N = 8 exercise cohort (green) and N = 6 
control cohort (red). The bars represent the 
mean ±SD. (c) NKp46 expression on the 
CD56dim CD16pos NK subset: median 
fluorescence index (MFI) changes from 
baseline. N = 4 exercise group and N = 4 
control group. The bars represent median 


















































































































CD56dimCD16pos NK cells – Median Fluorescence Intensity
Variable N Baseline 9– 12 weeks Within- group change Between- group change
Median (IQR) Median (IQR) Median (IQR) p- value
NKp46
Exercise 4 4.7 (4.0;8.5) 10.6 (8.3;13.0) 3.6 (3.4;7.5) 0.029
Control 4 5.8 (3.6;8.1) 5.1 (2.7;7.9) −0.7 (−3.0;2.0)
Abbreviations: EGFR, epidermal growth factor receptor; IQR, interquartile range; mAb, monoclonal antibody; MFI, median fluorescence index; PBMC, Peripheral 
blood mononuclear cell.
TABLE 1 (Continued)
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patients with metastatic prostate cancer (Pasero et al., 2015) 
and with acute myeloid leukemia (Fauriat et al., 2007). The 
considerable interest in exercise by both groups was reflected 
in the high proportion of history in sport participation conse-
quently our study sample may be somewhat biased towards 
a more active cancer population. We were unable to rule out 
potential contamination resulting from exercising patients 
in the control group, which might have underestimated the 
effect of the intervention on NK cell activity. However, we 
aimed to limit potential contamination by offering the exer-
cise intervention to the control group in the second half of 
the chemotherapy, and offering supervised moderate- high 
intensity exercise which may be more effective compared to 
home- based low- intensity (Waart et al., 2015). In conclusion, 
moderate- high intensity resistance and aerobic exercise dur-
ing chemotherapy has the potential to maintain NK cell func-
tion. For definite conclusions, findings should be replicated 
in a study powered for this purpose.
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